We observed and compared the differences in immune reconstruction between single-infusion anti-B-cell maturation antigen(BCMA), chimeric antigen receptor T cells(CAR-T), and combined infusion of anti-CD19 CAR-T cells in the treatment of recurrent/refractory multiple myeloma(RRMM). The gene discussed is TNFRSF17; the disease is AL amyloidosis.